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ABSTRACT
Objective: The objective of the present study was to synthesize a series of some novel (E)-methyl 2,4-dimethyl-5-(3-oxo-3-phenylprop-1-en-1-yl)-1H-
pyrrole-3-carboxylate derivatives and to evaluate it’s in vitro antimicrobial activities.
Methods: A novel series of (E)-methyl 2,4-dimethyl-5-(3-oxo-3-phenylprop-1-en-1-yl)-1H-pyrrole-3-carboxylate derivative (8a-l) has been 
synthesized by cyclization (Knorr reaction) hydrolysis, decarboxylation, and Vilsmeier–Haack formylation reaction. 5-formyl-2,4-dimethyl-1H-
pyrrole-3-carboxylate 6 undergo condensation with acetophenone derivatives 7a-l in methanol and potassium hydroxide. The synthesized compounds 
were screened for in vitro antimicrobial screening.
Results: The structures of the synthesized compounds were characterized by infrared, 1H nuclear magnetic resonance, and mass spectroscopy. The 
antimicrobial activity data revealed that the synthesized derivatives possess good antibacterial and antifungal activity which is attributed due to the 
presence of the heterocyclic ring; further, the activity increased with the introduction of a methoxy group in the structure.
Conclusions: New pyrrole chalcone derivatives act as significant antimicrobial agents, easy work-up procedure and reaction take place with minimum 
side product. Antimicrobial activity report provides an interesting template for the syntheses of new antimicrobial agents and may be helpful for the 
design of new therapeutic tools.
Keywords: Antimicrobial, Gram-positive, Gram-negative bacteria, Pyrrole chalcones.
INTRODUCTION
Heterocyclic compounds have a wide range of applications in 
pharmaceutical chemistry. Heterocyclic compounds have natural as well 
as synthetic source. Pyrrole has gain remarkable importance among the 
new heterocycles due to biological potential. Pyrrole has antimalarial 
and enzyme inhibition properties. Pyrrole is five-membered nitrogen-
containing heterocyclic compound. Colorless liquid compound and on 
exposing to air it becomes darken. It has importance in more complex 
macromolecules such as porphyrins of heme and chlorophyll. It was 
isolated from pyrolysate of bone. Its name came from Greek [1]. In 
recent years, there has been growing interest in chalcones and their 
important role in the prevention of various diseases such as cancer and 
chronic inflammation.
The chalcones are structurally simple and largest class of plant 
secondary metabolites, which serves as a defense mechanism in 
plants to counteract reactive oxygen species to prevent damage 
by micro-organisms [2]. Antimicrobial activity of bis-heterocyclic 
chalcones was tested against selective pathogens Escherichia coli, 
Candida albicans, and Aspergillus niger [3]. Several studies have 
pointed out the antimicrobial potential of chalcones against a wide 
range of fungi and bacteria, including resistant ones, clearly indicating 
that they are attractive target compounds for the discovery and 
development of new anti-infective agents [4-10]. These flavonoid 
family compounds display an impressive area of biological activities, 
among which antibacterial [11], antifungal [12], antioxidant [13,14], 
antileishmanial [15], antimalarial [16], angiogenesis inhibitor [17], anti-
inflammatory [18,19], antiviral [20], antimitotic [21], anticancer [22], 
anti-invasive [23,24], and antiproliferative [25]. Activities have been 
cited in the literature. Chalcones strongly inhibit the polymerization 
of tubulin by binding to the colchicine-binding site [16]. The α, 
β-unsaturated compounds may possess diverse pharmacological 
activities, and it has been found that the synthesized chalcones interact 
with the bovine serum albumin, a protein mainly responsible for the 
transportation of a number of compounds [26]. Substantial preliminary 
antibacterial activity was reported for the new chalcones at C8 of 
the coumarin nucleus, against Gram-positive and a Gram-negative 
bacteria [27]. In view of the pharmacological activities of phenothiazine, 
pyrazole, and pyrrole a number of the 2-substituted, pyrrole derivatives 
have been synthesized which contain pyrrole heterocycles [28].
Therefore, in view of these important biological activities of pyrrole 
scaffold. We reported the synthesis of some novel (E)-methyl 
2,4-dimethyl-5-(3-oxo-3-phenylprop-1-en-1-yl)-1H-pyrrole-3-
carboxylate derivatives and tested the antibacterial and antifungal 
activities of the new resulting compounds which have been found to 
possess an interesting profile of pharmacological activity, against 
Gram-negative, Gram-positive bacteria and fungi 8f, 8e, 8c. Chemically 
chalcones are open chain flavonoids in which the two aromatic rings 
are joined together by three carbons, α, and β-unsaturated carbonyl 
system. Fundamentally, they are considered as derivatives of phenyl 
styryl ketone. In view of the varied biological and pharmacological 
applications, we have synthesized some new (E)-methyl 2,4-dimethyl-5-
(3-oxo-3-phenylprop-1-en-1-yl)-1H-pyrrole-3-carboxylate derivatives. 
In general, chalcones contain C6–C3–C6 unit but the compounds 
reported in the present study contain C6–C3–C5 unit.
© 2019 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2019.v12i2.30275
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EXPERIMENTAL
METHODS
The melting points of all the synthesized compounds were determined 
in open capillary tubes and are uncorrected. The purity of all compounds 
was checked by thin-layer chromatography (TLC) Silica gel 60 F254. 
Infrared (IR) spectra were recorded on Fourier-transform IR (Model-
Nicolet iS-10 Mid) 1H NMR spectra were recorded on 400 MHz-NMR 
Spectrometer CDCl3/dimethyl sulfoxide (DMSO)-d6 (Bruker Biospin 
International AG); chemical shifts (δ) are in parts per million (ppm) 
relative to TMS and coupling constant (J) is expressed in hertz (Hz). Mass 
spectra were recorded on a Thermo Scientific Q-Exactive, Accela 1250 
pump, Macro mass spectrometer (Water, Milford, MA) by electrospray 
method (ES). TLC was performed on the and visualized in UV light. All 
chemicals and solvents were obtained from Spectrochem, Aldrich, or 
Merck and are of analytical grade, and were used freshly after opening.
Synthesis of diethyl 3, 5-dimethyl-1H-pyrrole-2,4-dicarboxylate (2)
To prepare diethyl 3, 5-dimethyl-1H-pyrrole-2,4-dicarboxylate, 
a mixture of acetic acid (40 ml) and ethyl acetoacetic ester 
1 (20 ml, 156 mmol) was added an aqueous solution of sodium nitrite 
(5.6 g, 81 mmol) in water (6 ml) cooled in an ice bath to keep the 
temperature of reaction mixture 5–10°C. The yellowish clear reaction 
mixture was kept for another 2.5 h at the same temperature to further 
complete reaction. Then, zinc powder (11 g, 52.34 mmol, 300 mesh) was 
added to this mixture portion wise while the reaction mixture was kept 
<25°C. It was then heated to 45–50°C for 10 min then continued slow 
heating to 95°C for another 1 h exotherm was observed. Cooled reaction 
mass to room temperature, the yellowish precipitate was collected and 
washed with ice water to remove the acetic acid. Recrystallized the 
yellow crude solid from ethanol to afford a pale yellow crystalline solid 
powder of pure 2 (35 g, yield 93%), mp. (melting point) 137–138°C. 
lit. mp. 135–136°C [29,30]. 1H NMR (400 MHz, CDCl3) δ 1.35–1.39 
(m, 6H, 2 X CH3), 2.52 (s, 3H, CH3), 2.57 (s, 3H, CH3), 4.27-4.36 (m, 4H, 2 
X CH2), 8.90 (s, 1H, -NH pyrrole).
Synthesis of 4-(ethoxycarbonyl)-3,5-dimethyl-1H-pyrrole-2-
carboxylic acid (3)
To prepare 4-(ethoxycarbonyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic 
acid, compound 2 (20 g, 83.6 mmol) was added into a flask equipped 
with a stirrer, a thermometer, and a condenser; absolute ethanol 
(120 ml) was added into the flask. An aqueous solution (240 ml) 
of potassium hydroxide (11.8 g, 210.3 mmol) was added heated at 
50–60°C for 10 h with monitoring by TLC until reaction completion. The 
reaction was then stopped by cooling down to room temperature. The 
reaction mixture was poured into ice-water (600 ml) to form an aqueous 
solution. A small amount of insoluble substance was filtered and kept 
aside. Aqueous layers were adjusted with hydrochloride (2 mol/L) to 
pH 4 to afford some white precipitates, which were collected through 
filtering and washing with ice-water to provide 3 (15 g, yield 85%), 
m. p. 169–170°C (lit. 235–236°C [30] (eluent: chloroform/methanol, 
v/v = 10:1).
Synthesis of 2, 4-dimethyl-1H-pyrrole-3-carboxylic acid (4)
To prepare 2,4-dimethyl-1H-pyrrole-3-carboxylic acid, compound 
3 (10 g, 47. 35 mmol) was added into flask equipped with a stirrer, a 
thermometer, and condenser; HCl (5 ml) and methanol (150 ml) were 
added into the flask and heated up to 75–80°C for 1.5 h with monitoring 
by TLC until completion of decarboxylation. The reaction was cooled 
down to room temperature, further cooled up to 0–5°C. Slowly added 
solution of KOH (8.8 g) dissolving in water (100 ml) and the reaction 
mass was heated at 60–65°C temperature for 5–6 h with monitoring 
by TLC until completion of hydrolysis. Stopped heating and cooled to 
room temperature. The reaction mass was extracted with ethyl acetate 
to remove impurities and separated aqueous layer was collected and 
acidified with 1:1 HCl to pH 3–4 to afford light brown solid precipitates, 
which was collected through filtering and washing with ice-water to 
provide compound 4 (5.5 g, yield 83%), m. p. 75–76°C (lit. 74–76°C [30] 
(eluent: chloroform/methanol, v/v = 10:1).
Synthesis of methyl 2,4-dimethyl-1H-pyrrole-3-carboxylate (5)
To prepare methyl 2,4-dimethyl-1H-pyrrole-3-carboxylate, compound 
4 (5.0 g, 35 mmol) was added into flask equipped with a stirrer, a 
thermometer, and condenser; H2SO4 (0.2 ml,) and methanol (75 ml) 
into the flask and heated up to 60–65°C for 1.5 h monitored by TLC 
until reaction completion. The reaction was then stopped by cooling 
down to room temperature, further cooled up to 0–5°C. The reaction 
mixture was poured into ice-water (100 ml) to afford light brown solid 
precipitates, which was collected through filtering and washing with 
ice-water to provide 5 (4.12g, 68%), m. p. 70–72°C (eluent: chloroform/
methanol, v/v = 10:1).
Synthesis of methyl 5-formyl-2,4-dimethyl-1H-pyrrole-3-
carboxylate (6)
Anhydrous DMF (2.5 ml, 200 mmol) in a dry flask was precooled to 0°C 
with a salt-ice bath, into which a solution of POCl3 (3.60 ml, 320 mmol) 
in anhydrous dichloromethane (10 ml) was added dropwise. The 
temperature should be kept <3°C during the whole addition process. The 
reaction mixture was stirred for 0.5 h using an ice-bath before dropwise 
addition of a solution of methyl 2,4-dimethyl- 1H-pyrrole-3-carboxylate 
5 (4.0, 26.11 mmol) in anhydrous dichloromethane (20.0 ml). The 
mixture was heated under reflux for 3 h and monitored by TLC until 
reaction completion. The reaction was then stopped by cooling down to 
room temperature, further cooled up to 0–5°C. Neutralize the reaction 
mixture using 30% aq. (Aqueous) potassium carbonate solution 
till pH 8–9. Stirred the reaction mass for 1 h at room temperature, 
separated the organic layer using separating funnel, extracted the 
aqueous layer with DCM (100 ml × 3 times) separated organic layer was 
washed with water (50 ml × 3 times) and separated organic layer was 
dried over sodium sulfate, distilled out DCM under vacuum completely 
to afford pale-gray solid, dried under vacuum to afford compound 
6 (4.5 g, yield 95%), m. p. 167–169°C (eluent: chloroform/methanol, 
v/v = 10:1). IR (KBr) cm−1: 3244 (-NH), 1698 (C=O), 1559 (C=C), 1H 
NMR (400 MHz, CDCl3) δ 2.569–2.592 (s, 6H,-CH3), 3.863 (s, 3H, -OCH3), 
9.637 (s, 1H, -CHO), 9.932 (s, 1H, NH).
General procedure for the synthesis of (E)-methyl 2,4-dimethyl-5-
(3-oxo-3-phenylprop-1-en-1-yl)-1H-pyrrole-3-carboxylate (8a-i)
An aqueous solution of KOH (0.093 g, 1.65 mmol) was added to cooled 
suspension of 1-(4-fluorophenyl) ethanone 7a (0.190 g, 1.38 mmol) 
and methanol-water mixture 5 ml (9.5:0.5), this mixture was stirred 
5–10°C for 30 min. After 30 min added methyl 5-formyl-2,4-dimethyl-
1H-pyrrole-3-carboxylate 6 (0.250 g, 1.38 mol). Raised temperature up 
to room temperature and the mixture was stirred at room temperature 
for overnight. The reaction mixture was poured into water. The solid 
product (8a) separated out was filtered off and washed with plenty of 
water finally crystallized from ethanol. The compounds (8a-i) were 
prepared by following the aforementioned procedure. Their structures 
have been confirmed by mass, IR, and 1H NMR spectra.
(E)-methyl 5-(3-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)-2,4-dimethyl-
1H-pyrrole-3- carboxylate (8a)
Yield: 75%; molecular formula (MF): C17H16FNO3/301.31; yellow solid; 
MP. 207–210°C; IR (KBr) cm−1: 3235 (-NH), 1696 (C=O), 1530 (C = C); 
1H NMR (400 MHz, DMSO-d6) δ 2.396 (s, 3H, -CH3), 2.574 (s, 3H, -CH3), 
3.838 (s, 3H, -OCH3), 6.978–7.016 (d, J = 15.2 HZ, 1H, ethylenic), 
7.100–7.143 (m, 2H, -Ar), 7.789–7.828 (d, J = 15.6HZ, 1H, ethylenic), 
7.978–8.014 (m, 2H, -Ar), 9.015 9 (s,1H, -NH); HRMS = 302.1187 [M+H].
(E)-methyl 2,4-dimethyl-5-(3-oxo-3-(3,4,5-trimethoxyphenyl) prop-
1-en-1-yl)-1H-pyrrole-3-carboxylate (8b)
Yield: 79%; MF: C20H23NO6/373.4; yellow solid; MP. 138–141°C; IR 
(KBr) cm−1: 3379 (-NH), 1675 (C=O), 1545 (C=C); 1H NMR (400 MHz, 
DMSO-d6) δ 2.412 (s, 3H, -CH3), 2.588 (s, 3H, -CH3), 3.842 (s, 3H, -OCH3), 
3.915–3.929 (s, 9H, -OCH3), 6.920–6.958 (d, J = 15.2 HZ, 1H, ethylenic); 
7.199–7.216 (d, 2H, -Ar); 7.794–7.833 (d, J = 15.6 HZ, 1H, ethylenic); 
8.939 (s,1H, -NH); HRMS = 374.1598 [M+H].
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(E)-methyl 5-(3-(4-cyanophenyl)-3-oxoprop-1-en-1-yl)-2,4-dimethyl-
1H-pyrrole-3-carboxylate(8c)
Yield: 69%; MF: C18H16N2O3/308.33; yellow solid; MP.218–220°C; 
IR(KBr) cm−1: 3338 (-NH), 2235 (CN), 1698 (C=O), 1555 (C=C); 1H 
NMR (400MHz, DMSO-d6) δ 2.368 (s, 3H, -CH3), 2.529 (s, 3H, -CH3), 
3.791(s, 3H, -OCH3), 7.243–7.81(d, J = 15.2 Hz 1H, ethylenic), 7.732–
7.753 (d, 2H, -Ar), 7.765–7.804 (d, J = 15.6 Hz 1H, ethylenic), 8.083–
8.104 (d, 2H, -Ar) 10.862 (s,1H, -NH); HRMS = 309.1234 [M+H].
(E)-methyl 2,4-dimethyl-5-(3-(4-nitrophenyl)-3-oxoprop-1-en-1-
yl)-1H-pyrrole-3-carboxylate (8d)
Yield: 71%; MF: C17H16N2O5/328.32; orange solid; MP. 99–101°C; IR 
(KBr) cm−1: 3218 (-NH), 1687 (C=O), 1558 (C=C); 1H NMR (400 MHz, 
DMSO-d6) δ 2.418 (s, 3H, -CH3), 2.598 (s, 3H, -CH3), 3.848 (s, 3H, -OCH3), 
6.926–6.964 (d, J = 15.2 HZ, 1H, ethylenic), 7.821–7.859 (d, J = 15.2 HZ, 
1H, ethylenic), 8.082-8.104 (d, J = 8.8Hz, 2H, -Ar); 8.300-8.322(d, J = 8.8, 
2H, -Ar), 8.952 (s, 1H, -NH); HRMS = 329.1132 [M+H].
(E)-methyl 5-(3-(4-chlorophenyl)-3-oxoprop-1-en-1-yl)-2,4-dimethyl-
1H-pyrrole-3-carboxylate (8e)
Yield: 72%; MF: C17H16ClNO3/317.76; brownish yellow solid; MP. 
170–172°C; IR(KBr) cm−1:3258 (-NH), 1697 (C=O), 1530 (C=C); 1H 
NMR (400 MHz, DMSO-d6) δ 2.4 (s, 3H, -CH3), 2.6 (s, 3H, -CH3), 3.839 
(s, 3H, -OCH3), 6.954–6.992 (d, J = 15.2 HZ 1H, ethylenic), 7.405–7.426 
(d, J = 8.4 HZ 2H, -Ar), 7.789–7.827 (d, J = 15.2 HZ 1H, ethylenic), 7.909–




Yield: 67%; MF: C18H19NO4/313.34; yellow solid; MP.179–180°C; 
IR(KBr) cm−1: 3191 (-NH), 1699 (C=O), 1534 (C=C); 1H NMR (400 MHz, 
DMSO-d6) δ 2.396 (s, 3H, -CH3), 2.570 (s, 3H, -CH3), 3.849 (s, 3H, -OCH3), 
3.882 (s, 3H, -OCH3); 6.904–6.925 (d, J = 8.4 HZ 2H, -Ar), 7.041–7.080 
(d, J = 15.6 HZ 1H, ethylenic), 7.787–7.826 (d, J = 15.6 HZ 1H, ethylenic), 




Yield: 65%; MF: C19H21NO5/343.37; yellow solid; MP.137–139°C; 
IR(KBr) cm−1: 3225 (-NH), 1693 (C=O), 1536 (C=C); 1H NMR (400 
MHz, DMSO-d6) δ 2.375(s, 3H, -CH3), 2.558 (s, 3H, -CH3); 3.865(s, 
9H, -OCH3); 6.477–6.483 (d, 1H, -Ar), 6.536–6.558 (d, J = 8.8 HZ 1H, -Ar), 
6.942–6.981 (d, J = 15.6 HZ 1H, ethylenic), 7.637–.637 (d, J = 15.6 Hz 




Yield: 61%; MF: C17H17NO3/283.32; yellow solid; MP.150–153°C; IR(KBr) 
cm−1: 3222 (-NH), 1698 (C=O), 1540 (C=C); 1H NMR (400 MHz, DMSO-d6) 
δ 2.401 (s, 3H, -CH3); 2.575 (s, 3H, -CH3), 3.837(s, 3H, -OCH3), 7.017–
7.056 (d, J = 15.6 Hz 1H, ethylenic), 7.435–7.473 (m, 2H, -Ar), 7.526–
7.566 (m, 1H, -Ar), 7.796–7.834 (d, J = 15.2 HZ 1H, ethylenic), 7.956–
7.976 (d, J = 8 Hz 2H -Ar), 9.052 (s, 1H, -NH); ESI-MS:284.2000 [M+H].
(E)-methyl 2, 4-dimethyl-5-(3-oxo-3-(p-tolyl)prop-1-en-1-yl)-1H-
pyrrole-3-carboxylate (8i)
Yield: 59%; MF: C18H19NO3/297.34; yellow solid; MP.178–181°C; 
IR(KBr) cm−1: 3195 (-NH), 2985 (-CH), 1693 (C=O), 1539 (C=C); 1H NMR 
(400 MHz, DMSO-d6) δ 2.404 (s, 6H, -CH3), 2.563 (s, 3H, -CH3), 3.831(s, 
3H, -OCH3), 7.056–7.095 (d, J = 15.6 Hz 1H, ethylenic), 7.212–7.232 (d, J 
= 8 Hz 2H -Ar), 7.784–7.823 (d, J = 15.6 Hz 1H, ethylenic), 7.861–7.881 
(d, J = 8 Hz 2H, -Ar), 9.269 (s,1H, -NH); ESI-MS: 298.20 [M+H].
(E)-methyl 5-(3-(2,5-dimethoxyphenyl)-3-oxoprop-1-en-1-yl)-2,4-
dimethyl-1H-pyrrole-3-carboxylate (8j)
Yield: 60%; MF: C19H21NO5/343.37; yellow solid; MP.122–124°C; 
IR(KBr) cm−1: 3252 (-NH), 1682 (C=O), 1546 (C=C); 1H NMR (400 MHz, 
DMSO-d6) δ 2.356 (s, 3H, -CH3), 2.552 (s, 3H, -CH3), 3.825 (s, 9H, -OCH3), 
6.860–6.899 (d, J =15.61 HZ 1H, ethylenic), 6.904–7.008 (m, 2H -Ar), 
7.121–7.128 (d, 1H, -Ar), 7.580–7.620 (d, J = 16 Hz 1H, ethylenic), 9.003 
(s, 1H, -NH); HRMS = 344.1437 [M+H].
Scheme 1: Synthetic scheme, reagent, and conditions: (a) (i) NaNO2, (ii) AcOH, Zn, 90–95°C, (b) Aq. KOH, EtOH, 50–60°C, (c) (i) HCl, MeOH, 
75–80°C, (ii) Aq.KOH, MeOH, 60–65°C, (d) Cat.H2SO4, MeOH, 60–65°C, (e) DMF/POCl3, DCM, reflux, (f) Aq.KOH, MeOH, r.t.
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(E)-methyl 2,4-dimethyl-5-(3-(3-nitrophenyl)-3-oxoprop-1-en-1-
yl)-1H-pyrrole-3-carboxylate (8k)
Yield: 57%; MF: C17H16N2O5/328.31; yellow solid; MP.102–105°C; IR 
(KBr) cm−1: 3218 (-NH), 1687(C=O), 1558 (C=C); 1H NMR (400 MHz, 
DMSO-d6) δ 2.446 (s, 3H, -CH3), 2.632 (s, 3H, -CH3), 3.855 (s, 3H, -OCH3), 
6.959–6.997 (d, J = 15.2 HZ 1H, ethylenic), 7.688–7.728 (m, 1H, -Ar), 
7.898–7.936 (d, J = 15.2 HZ 1H, ethylenic), 8.357–8.438 (m, 3H, -Ar), 
8.817 (s, 1H, -NH).
(E)-methyl 2,4-dimethyl-5-(3-oxo-3-(3,4,5-trimethylphenyl)prop-
1-en-1-yl)-1H-pyrrole-3-carboxylate (8l)
Yield: 55%; MF: C20H23NO3/325.40; yellow solid; MP.147–150°C; IR 
(KBr) cm−1: 3195 (-NH), 2985 (-CH), 1693 (C=O), 1539 (C=C); 1H 
NMR (400 MHz), DMSO-d6) δ 2.404 (s, 6H, -CH3), 2.563 (s, 9H, -CH3), 
3.831 (s, 3H, -OCH3), 7.056–7.095 (d, J = 15.6 Hz 1H, ethylenic), 7.212–
7.232 (s, 1H, -Ar), 7.784–7.823(d, J = 15.6 Hz 1H, ethylenic), 7.861–
7.881(s, 1H, -Ar); 9.269 (s, 1H, -NH).
Biological evaluation
Antibacterial and antifungal activity
Some of the synthesized compounds were screened for in vitro 
antibacterial and antifungal activities against Gram-positive and 
Gram-negative bacteria. In Gram-positive bacteria, Micrococcus luteus, 
Bacillus megaterium, Staphylococcus aureus, and Bacillus cereus 
were used and in Gram-negative bacteria, Salmonella typhi, E. coli, 
Pseudomonas aeruginosa, and Salmonella abony were used against 
standard tetracycline. In antifungal activity C. albicans, Saccharomyces 
cerevisiae and Aspergillus niger were used against standard nystatin. 
Antimicrobial activities were carried out on nutrient agar with standard 
composition and by standard procedure of paper disk method [31].
Petri dishes and necessary glassware’s were sterilized in hot air oven 
(190°C, 45 min). The nutrient agar and saline (0.82% NaCl) were 
sterilized in an autoclave (121°C, 15 psi, and 20 min). The inoculum 
was prepared in sterile saline, and optical density of all pathogens 
was adjusted to 0.10 at 625 nm on Chemito Spectra scan UV 2600 
spectrometer (Mumbai, India), which is equivalent to 0.5 McFarland 
standards. The nutrient agar plates were prepared by pour plate 
method [31]. The sensitivity of compounds was tested by the disk 
diffusion method (paper disk method). All the bacterial cells were 
cultured in nutrient plates and the compounds to be tested were 
dissolved in DMSO solvent and were soaked in paper disks. The disks 
were placed into the plates and incubated at 37°C for 24 h. The diameter 




The synthesis of (E)-methyl 2,4-dimethyl-5-(3-oxo-3-phenylprop-1-en-
1-yl)-1H-pyrrole-3-carboxylate derivatives (8a-8l) Scheme 1. Diethyl 
3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate (2) was first obtained through 
Knorr reaction from acetyl acetate ethyl ester (1) and zinc and acetic acid. 
The diethyl 3,5-dimethyl-1H-pyrrole-2,4-dicarboxylate (2) has selectively 
hydrolyzed by KOH in ethyl alcohol to yield 4-(ethoxycarbonyl)-3,5-
dimethyl-1H-pyrrole-2-carboxylic acid (3). The 4-(ethoxycarbonyl)-
3,5-dimethyl-1H-pyrrole-2-carboxylic acid was further subjected 
to decarboxylation reaction in the presence of hydrochloric acid 
in methanol and which on further hydrolysis in the presence of 
potassium hydroxide yield 2,4-dimethyl-1H-pyrrole-3-carboxylic acid 
compound (4). Compound 4 on esterification reaction using H2SO4 and 
methanol to form methyl 2,4-dimethyl-1H-pyrrole-3-carboxylate (5). 
Compound 5 further subjected to Vilsmeier–Haack formylation reaction 
to afford methyl 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylate (6). 
The methyl 5-formyl-2,4-dimethyl-1H-pyrrole-3-carboxylate was 
subjected to base-catalyzed Claisen-Schmidt condensation reaction [32], 
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3-carboxylate derivatives (8a-l). The purity of compounds was checked by 
TLC. Analytical and spectral data (1HNMR, IR, mass) of newly synthesized 
compounds were in full agreement with the proposed structure. The 
structure of 6 is interpreted from spectroscopic data its NMR spectrum 
exhibit characteristics of the aldehydic proton at δ = 9.6 ppm and -NH 
pyrrole peaks at δ = 9.9 ppm. The structure of 8a is interpreted from 
spectroscopic data. The IR spectrum of 8a shows characteristic bands at 
1696 due to C=O stretching. Its 1H NMR spectrum exhibits the presence 
of olefinic protons as a doublet at δ = 7.0 and 7.8 regions with a mutual 
coupling constant value (J = 15.2 and 15.6 Hz). These observed coupling 
constant values indicate the presence of E- configuration from the 
structure and the remaining protons as well aliphatic protons appear 
at their respective position. The -NH is highly deshielded and appears 
at δ = 9.01 ppm. Mass spectrum of (E)-methyl 5-(3-(4-fluorophenyl)-
3-oxoprop-1-en-1-yl)-2,4-dimethyl-1H-pyrrole-3- carboxylate showed 
(M+H) peak at 302.11.
Antimicrobial activity
Antimicrobial activity result of synthesized(E)-methyl 2,4-dimethyl-5-
(3-oxo-3-phenylprop-1-en-1-yl)-1H-pyrrole-3-carboxylate (8a-l) reveals 
that the compounds 8f, 8e, and 8c were found to possess significant 
activity while 8a, 8d, 8g, and 8k showed moderate to good activity 
compared to the standard reference nystatin and tetracycline Table 1.
The diameter in millimeter of the zone of inhibition around each disk 
was measured by a scale, and the observed data of antimicrobial and 
antifungal activities of compounds and the standard drugs are given 
in Table 1. Among all the compound screened 8f, 8e, and 8c showed 
significant antibacterial activity against Gram-positive bacteria.
Solvent used-DMSO-The effect of DMSO on pathogen was also checked, 
but it was found that DMSO does not affect the pathogen.
The concentration of compounds used for the test - 1 mg/ml.
All results (zone of inhibition) are recorded in millimeter (mm).
Compounds 8a and 8f showed significant activity against Gram-negative 
bacteria as comparable with that of standard drug tested. Compounds 
8c, 8e, 8f, 8g, and 8k showed good activity against fungal pathogens 
as compared with that of standard drug tested. Hence, the result 





1H-pyrrole-3-carboxylate (8e) moiety represent a new class of 
pharmacophore for broad spectrum of antimicrobial activity.
CONCLUSION
In summary, we have synthesized a series of pyrrole incorporated 
new (E)-methyl 2,4-dimethyl-5-(3-oxo-3-phenylprop-1-en-1-yl)-
1H-pyrrole-3-carboxylate derivatives(8a-l), and their antimicrobial 
activities have been evaluated. The compounds 8f, 8e, and 8c 
demonstrated significant inhibition and 8a, 8d, 8g, and 8k showed 
moderate to good activity against the tested strains. The importance 
of such work lies in the possibilities that the new compounds might 
be more efficacious drugs against bacteria, which could be helpful in 
designing more potent antibacterial agent for therapeutic use.
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